Clinical Trial Update: A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating IMU-131 (HER-Vaxx) with chemotherapy or pembrolizumab in metastatic HER2-overexpressing gastric cancer; the trial was terminated and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Stomach Cancer

Drugs mentioned

• IMU-131 (HER-Vaxx) (IMU-131)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Imugene Limited | Conditions: Gastric Cancer, Cancer of Stomach | Phase 2 | Status: TERMINATED | Results posted: 2025-05-11